Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2710-2717

  Aeschlimann, Jeffrey R ^a,b   Zervos, Marcus J ^c,d   Rybak, Michael J ^a,b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; QUINUPRISTIN; RP 54496; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0031658032     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2710     Document Type: Article

References (41)

1. Aeschlimann, J. R., J. Rebuck, and M. J. Rybak. 1997. Pharmacodynamic analysis of quinupristin/dalfopristin (Q/D, Synercid) versus vancomycin-resistant Enterococcus faecium with differing MBCs using time-kill curve (KC) and postantibiotic effect (PAE) methods, abstr. E-136, p. 138. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Allignet, J. and N. El Solh. 1995. Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, vatB. Antimicrob. Agents Chemother. 39:2027-2036.
3. Aumercier, M., S. Boulhallab, M. L. Capmau, and F. Le Goffic. 1992. RP 59500: a proposed mechanism for its bactericidal activity. J. Antimicrob. Chemother. 30(Suppl. A):9-14.
4. Barriere, J. C., D. H. Bouanchaud, J. M. Paris, et al. 1992. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J. Antimicrob. Chemother. 30(Suppl. A.):1-8.
5. Bergeron, M., and G. Montay. 1997. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and humans. J. Antimicrob. Chemother. 39(Suppl. A):129-138.
6. Blaser, J. In vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 25:57-68
7. Boswell, F. J., J. Sunderland, J. M. Andrews, and R. Wise. 1997. Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods. J. Antimicrob. Chemother. 39(Suppl. A):29-32.
8. Bouanchaud, D. H. 1992. In vitro and in vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J. Antimicrob. Chemother. 30(Suppl. A):95-99.
9. Bouanchaud, D. H. 1997. In vitro and in vivo antibacterial activity of quinupristin/dalfopristin. J. Antimicrob. Chemother. 39(Suppl. A):15-21.
10. Caron, F., H. S. Gold, C. B. Wennersten, M. G. Farris, R. C. Moellering, and G. M. Eliopoulos. 1997. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 41:2749-2753.
11. Caron, F., H. S. Gold, C. B. Wennersten, R. C. Moellering, and G. M. Eliopoulus. 1996. Role of growth phase and erythromycin susceptibility on the bactericidal effect of RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant Enterococcus faecium, abstr. 6.17, p. 60. In Program and Abstracts of the Third International Conference on Macrolides, Azalides, and Streptogramins. Lisbon, Portugal.
12. Centers for Disease Control and Prevention. 1993. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42:597-599.
13. Chant, C., and M. J. Rybak. 1995. Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann. Pharmacother. 29:1022-1027.
14. Chow, J. W., S. Donabedian, and M. J. Zervos. 1997. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin. Infect. Dis. 24:90-91.
15. Cunha, B. A., C. M. Sibley, and A. M. Ristuccia. 1982. Doxycyclme. Ther. Drug Monit. 4:115-135.
16. Entenza, J. M., H. Drugeon, M. P. Glauser, and P. Moreillon. 1995. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob. Agents Chemother. 39:1419-1424.
17. Fantin, B., R. LeClercq, L. Garry, and C. Carbon. 1997. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob. Agents Chemother. 41:931-935.
18. Fantin, B., R. Leclercq, Y. Merle, et al. 1995. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin/ dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. 39:400-405.
19. Fantin, B., R. Leclercq, M. Ottaviani, et al. 1994. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob. Agents Chemother. 38:432-437.
20. Hospital Infection Control Practices Advisory Committee. 1995. Recommendations for preventing the spread of vancomycin resistance. Infect. Control Hosp. Epidemiol. 16:105-113.
21. Jones R. N., C. H. Ballow, D. Biedenbach, J. J. Schentag, and the SMART Study Group. 1997. Streptogramin combination (quinupristin/daltopristin) activity and spectrum from a 1997 study in over 200 medical centers: analysis for regional variations, co-resistances, and validity of proposed susceptibility breakpoints, abstr. E-134, p. 137. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Kang, S. L. and M. J. Rybak. 1995. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro infected fibrin clot model. Antimicrob. Agents Chemother. 39:1505-1511.
23. LeClercq, R., and P. Courvalin. 1996. Emerging problems with enterococcal infections. Curr. Opin. Infect. Dis. 9:115-119.
24. Leclerq, R. E. Deroit, J. Duval, and P. Courvalin. 1988. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319:157-161.
25. Leclercq, R., L. Nantas, C. J. Soussy, and J. Duval. 1992. Activity of RP 59500, a new patenteral semisynthetic streptogramin against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J. Antimicrob. Chemother. 30(Suppl. A):67-76.
26. Liebowitz, B., J. L. Hakes, M. M. Cahn, et al. 1972. Doxycycline blood levels in normal subjects after intravenous and oral administration. Curr. Ther. Res. Clin. Exp. 14:820-831.
27. McGrath, B. J., S. L. Kang, G. W. Kaatz, and M. J. Rybak. 1994. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureuis in an in vitro pharmacodynamic model of endocarditis. Antimicrob. Agents Chemother. 38:2034-2040.
28. Megran, D. W. 1992. Enterococcal endocarditis. Clin. Infect. Dis. 15:63-71.
29. Millichap, J., T. Ristow, U. Bodner, et al. 1995. Selection of Enterococcus faecium strains with stable and unstable resistance to RP 59500 using stepwise exposure in vitro, abstr. E-120, p. 106. In Abstracts ot the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Millichap, J., T. A. Ristow, G. A. Noskin, and L. R. Peterson. 1996. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure. Diagn. Microbiol. Infect. Dis. 25:15-20.
31. Moellering, R. L., and P. K. Linden. 1998. Efficacy and safety of quinupristin/ dalfopristin (Synercid) in the treatment of vancomycm-resistant Enterococcus faecium (VREF) infections, abstr. 2.14. p. 30. In Program and Abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins, and Ketolides. Barcelona, Spain.
32. Nadler, H., M. Dowzicky, G. Talbot, F. Bompart, and F. Grote. 1997. Low rates of emerging resistance and superinfection in Synercid (quinupristin/ dalfopristin Q/D) treated patients during worldwide clinical program, abstr. E-136B, p. 5. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
33. National Committee for Clinical Laboratory Standards. 1993. Approved standard Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Laboratory Standards, Villanova, Pa.
34. Nicolau, D. P., C. D. Freeman, C. H. Nightingale, C. J. Coe, and R. Quintilliani. 1994. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38:1515.
35. Piper, J., K. Furness, L. Steele-Moore, and D. Ferris. 1997. Quinupristin/ dalfopristin (Synercid) resistant vancomycin resistant Enterococcus faecium (SRVRE), abstr. C-80, p. 60. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Piper, J., L. Steele-Moore, and D. Berg. 1996. Acquired resistance to quinupristin/dalfopristin (Synercid®) during successful antimicrobial therapy ot vancomycin-resistant enterococcus (VRE), abstr. A-109, p. 152. In Abstracts of the 96th General Meeting of the American Society for Microbiology. American Society for Microbiology,. Washington,. D.C.
37. Rosato, A., H. Vicarini, and R. Leclereq. 1996. High level cross-resistance to macrolides and lincomycin in streptococci and enterococci: constitutive or inducible expression of ribosomal methylase?, abstr. C-81, p. 49. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
38. Smith, C. L., P. E. Warburton, A. Gaal, and C. R. Cantor. 1986. Analysis of genome organizations and rearrangements by pulsed field gradient gel electrophoresis, p. 45-70. In J. K. Setlow and A. Hollaender (ed.), Genetic engineering, principles and methods. Plenum Press, New York, N.Y.
39. Thal, L. A., A. Davison, J. Chow, and M. Zervos. 1996. In vitro evaluation ot the development of Synercid® resistant mutants in Enterococcus faecium, abstr. 165, p. 66. In Abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America. New Orleans, La.
40. Uttley, A. H. C., C. H. Collins, J. Naidoo, et al. 1988. Vancomycin-resistant enterococci. Lancet i:57-58.
41. Williams, J. D., J. P. Maskell, A. C. Whiley, and A. M. Sefton. 1997. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. J. Antimicrob. Chemother. 39(Suppl. A):41-46.